Search the Newsreel

Organon & Co To Go Ex-Dividend On August 14th, 2026 With 0.02 USD Dividend Per Share

Organon & Co will go ex-dividend on August 14th, 2026. The company is set to pay a dividend of 0.02 USD per share. This indicates a forthcoming dividend payment for shareholders.

Cognex CEO Matthew Moschner Executes Stock Option Exercises and Sells 28,562 Shares Under Rule 10b5-1 Plan

Cognex Corp CEO Matthew Moschner exercised stock options and sold 28,562 shares of common stock on August 11, 2026, under a Rule 10b5-1 trading plan. These transactions resulted in his direct beneficial ownership decreasing to 10,884 shares of Cognex Common Stock. The sales and …

Earnings call transcript: Sera Prognostics misses Q2 2026 estimates as growth builds

Sera Prognostics earnings missed by $0.03, revenue fell short of estimates

Sera Prognostics (NASDAQ:SERA) Releases Quarterly Earnings Results, Misses Expectations By $0.03 EPS

Sera Prognostics, Inc. (SERA) Reports Q2 Loss, Misses Revenue Estimates

Sera Prognostics Reports Q2 Revenue of $30000 and $9.1 Million Net Loss

Sera Prognostics Q2 2026 Earnings: Commercial Progress Has Yet to Produce Material Revenue

Sera Prognostics (SERA) deepens Q2 2026 loss but extends cash runway to 2029

Cognex (CGNX) CEO Moschner sells 24,962 shares after exercising options

Cognex (CGNX) CEO & President Matthew Moschner exercised 16,600 stock options and sold 24,962 shares of common stock on August 11, 2026, generating approximately $1.60 million in gross sale proceeds. These transactions were executed under a pre-arranged Rule 10b5-1 trading plan. Despite the sales, …

Sera Prognostics Analysis Shows 22% Fewer NICU Admissions

Organon & Co. (OGN) CMO exercises 11,519 RSUs and withholds 4,134 shares for costs

Organon & Co.'s Chief Medical Officer, Juan Camilo Arjona Ferreira, exercised 11,519 restricted stock units (RSUs) on August 11, 2026, converting them into common shares. Concurrently, 4,134 common shares were withheld at $13.62 per share to cover exercise costs or tax liabilities. This transaction …

Why Cognex Corporation (CGNX) Stock Is Down Today

Why Cognex (CGNX) Shares Are Sliding Today What Happened? Shares of machine vision technology company Cognex (NASDAQ:CGNX) fell 4% in the afternoon session after HSBC downgraded the stock to "Hold" from "Buy" and slashed its price target. The bank adjusted its price target on …

Why Cognex (CGNX) Shares Are Sliding Today

Why Cognex (CGNX) Shares Are Sliding Today What Happened? Shares of machine vision technology company Cognex (NASDAQ:CGNX) fell 4% in the afternoon session after HSBC downgraded the stock to "Hold" from "Buy" and slashed its price target. The bank adjusted its price target on …

DOGZ Stock Stirs As Traders Target Low-Float Volatility

Cognyte to Unveil AI-Powered Financial Crimes Investigation Tech at IAFCI 2026

Cognyte is set to introduce its new AI-powered financial crimes investigation technology at the IAFCI 2026 conference. This development highlights the company's focus on leveraging artificial intelligence to combat financial crime.

CGTX FY2026 EPS Forecast Raised by Brookline Capital Markets

Brookline Capital Markets has increased its FY2026 EPS estimate for Cognition Therapeutics (NASDAQ:CGTX) to a loss of $0.42 per share, an improvement from their previous forecast of a $0.44 loss, though still below the consensus of a $0.34 loss. The company recently reported a …

Royal Bank of Canada Sells 18,885 Shares of Cognex Corporation $CGNX

Royal Bank of Canada reduced its stake in Cognex Corporation (NASDAQ:CGNX) by 13.5%, selling 18,885 shares but still holding 121,253 shares valued at $5.94 million. Institutional investors collectively own 88.12% of Cognex, with several other firms increasing their holdings, while a company VP also …

Inline Camera Inspection System Market for Food & Beverage and Pharmaceutical Industries by Component - Global Forecast to 2032

Company Logo The global inline camera inspection systems market is forecast to grow from USD 1.78 billion in 2026 to USD 3.04 billion by 2032, at a 9.4% CAGR. Growth is driven by AI-enabled machine vision, automated quality control, packaging verification, OCR/OCV, defect detection …

Organon & Co. $OGN Shares Purchased by California State Teachers Retirement System

California State Teachers Retirement System significantly increased its stake in Organon & Co. ($OGN) by 34.8% in the first quarter, bringing its total holdings to 327,075 shares valued at approximately $1.96 million. Despite institutional investors collectively owning 77.43% of the company, analyst sentiment remains …

Organon & Co (OGN) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cognex (CGNX) holder files Form 144 to sell option and RSU shares

A shareholder of Cognex Corporation (CGNX) has filed a Form 144 to sell 16,600 shares obtained from stock options and 8,362 shares related to restricted stock units. The sale will be executed as cash transactions on NASDAQ through Morgan Stanley Smith Barney LLC Executive …

Cognex (CGNX) VP Long reports 2,500 RSUs vested and 734 shares withheld for taxes

Cognex (CGNX) Vice President Darren Marc Long reported the vesting of 2,500 restricted stock units (RSUs) into common stock on August 7, 2026. Concurrently, 734 shares were withheld at $66.89 per share to cover tax obligations. The filing also details Long's ongoing direct holdings, …

Cognyte to Showcase Financial Crimes Investigation Technology at IAFCI International Conference

Cognyte Software Ltd. will showcase its financial crimes investigation technology, including its AI-powered NEXYTE platform, at the 2026 IAFCI International Conference. The company, a Gold Sponsor, will also host a speaking session on breaking down silos in financial crime investigations. Their solutions aim to …

MIUDELLA’s hormone-free IUD requires provider training before use

Organon has launched the Risk Evaluation and Mitigation Strategy (REMS) Program for its hormone-free copper intrauterine device (IUD), MIUDELLA, ahead of its anticipated commercial availability in late 2026. This program mandates training and certification for healthcare providers, healthcare settings, and eligible specialty pharmacies to …

Organon Opens REMS Program for MIUDELLA® Ahead of Anticipated Commercial Availability

Healthcare Providers, Healthcare Settings, and Participating Pharmacies Can Now Begin Required Training and Certification in Preparation for MIUDELLA's Launch Later This Year JERSEY CITY, N.J., August 11, 2026--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions …

DA Davidson raises Cognex stock price target on improved demand outlook

DA Davidson has increased its price target for Cognex (NASDAQ:CGNX) to $65 from $62, while maintaining a Neutral rating, following an improved demand outlook and strong second-quarter 2026 earnings. The firm revised its sales and EPS projections upwards for 2026 and 2027, aligning with …

Cognex Corp (CGNX) Shares Fall 3.8% -- What GF Score of 72 Tells Investors

Cognex Corp (CGNX) shares dropped 3.8%, making its current price of $64.36 23.7% above its GF Value of $52.05, suggesting the stock is "Modestly Overvalued." The company has a GF Score of 72/100, indicating an "Above Average" quality, primarily due to strong profitability and …

Cognex Sees Record Revenue, Margin Gains as AI Powers Machine-Vision Growth

Cognex (NASDAQ:CGNX) is experiencing record revenue and margin expansion, driven by strong demand in machine vision and the integration of AI. The company reported record second-quarter revenue of $290 million, with third-quarter guidance projecting another record at $310 million, and has significantly improved its …

Organon earnings in focus as Sun Pharma deal looms

Organon & Co. is reporting its second-quarter earnings, with analysts expecting $0.90 per share on $1.57 billion in revenue. Investors will be closely watching for operational improvements and stabilization in the women’s health franchise, especially given the impending $11.75 billion acquisition by Sun Pharmaceutical. …

CGNX Q2 Deep Dive: AI-Driven Growth and Product Diversification Shape Outlook

CGNX Q2 Deep Dive: AI-Driven Growth and Product Diversification Shape Outlook Machine vision technology company Cognex (NASDAQ:CGNX) fell short of the market's revenue expectations in Q2 CY2026, but sales rose 16.9% year on year to $291.3 million. On the other hand, next quarter's outlook …

COGNEX CORP COGNEX ORD SHS (0I14.L) Q1 FY2026 earnings call transcript

Cognex Corporation reported strong Q1 2026 results with a 24% year-over-year revenue increase and a significant expansion in adjusted EBITDA margin to 26.9%. The company raised its Q2 guidance, projecting 16.5% revenue growth, but maintained a cautious full-year outlook due to macroeconomic uncertainties and …

Why Cognex (CGNX) Could Be 17% Undervalued Following Its Raised Outlook

Cognition Therapeutics Inc (CGTX) Earnings Forecast: Future EPS & Revenue Growth Estimates

Cognition Therapeutics Inc (CGTX) Stock News Today

This article provides an overview of Cognition Therapeutics Inc (CGTX) stock information, including its current price, market capitalization, and a note that more news is coming soon. It highlights where to find news, earnings, analyst ratings, and key developments for the company.

Cognition Therapeutics, Inc. (CGTX) stock price, news, quote and history

This Yahoo Finance page provides comprehensive information on Cognition Therapeutics, Inc. (CGTX), including its current stock price, historical data, company overview, financial performance, and analyst ratings. CGTX is a clinical-stage biopharmaceutical company developing therapeutics for age-related degenerative diseases, with its lead candidate zervimesine in …